FIM
ALXN

Freedom Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Freedom Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,718
Closed -$1.05M – 942
2021
Q2 		$1.05M Sell
5,718
-497
-8% -$85.3K 0.08% 317
2021
Q1 		$950K Sell
6,215
-3,709
-37% -$574K 0.07% 316
2020
Q4 		$1.55M Sell
9,924
-577
-5% -$74.1K 0.17% 127
2020
Q3 		$1.2M Sell
10,501
-701
-6% -$75.6K 0.13% 154
2020
Q2 		$1.26M Sell
11,202
-2,451
-18% -$260K 0.14% 141
2020
Q1 		$1.37M Buy
13,653
+419
+3% +$41.1K 0.12% 159
2019
Q4 		$1.43M Sell
13,234
-1,637
-11% -$175K 0.13% 162
2019
Q3 		$1.46M Sell
14,871
-2,861
-16% -$322K 0.13% 160
2019
Q2 		$2.32M Sell
17,732
-1,005
-5% -$130K 0.19% 112
2019
Q1 		$2.53M Buy
18,737
+103
+0.6% +$12.8K 0.2% 100
2018
Q4 		$1.81M Sell
18,634
-1,396
-7% -$165K 0.14% 140
2018
Q3 		$2.39M Sell
20,030
-782
-4% -$98.1K 0.15% 127
2018
Q2 		$2.58M Buy
20,812
+14,056
+208% +$1.64M 0.16% 113
2018
Q1 		$753K Buy
6,756
+125
+2% +$14.9K 0.04% 462
2017
Q4 		$793K Buy
6,631
+170
+3% +$20.7K 0.04% 464
2017
Q3 		$906K Sell
6,461
-315
-5% -$42.8K 0.05% 370
2017
Q2 		$824K Buy
6,776
+38
+0.6% +$4.42K 0.05% 387
2017
Q1 		$817K Sell
6,738
-781
-10% -$101K 0.05% 365
2016
Q4 		$920K Sell
7,519
-1,919
-20% -$235K 0.06% 268
2016
Q3 		$1.16M Sell
9,438
-289
-3% -$37.2K 0.07% 202
2016
Q2 		$1.14M Buy
9,727
+400
+4% +$56.8K 0.08% 189
2016
Q1 		$1.3M Sell
9,327
-647
-6% -$95K 0.09% 160
2015
Q4 		$1.9M Sell
9,974
-10,740
-52% -$1.88M 0.14% 91
2015
Q3 		$102K Buy
20,714
+14,164
+216% +$2.58M 0.01% 656
2015
Q2 		$1.18M Buy
6,550
+1,856
+40% +$320K 0.12% 127
2015
Q1 		$814K Buy
4,694
+2,334
+99% +$422K 0.09% 181
2014
Q4 		$437K Buy
+2,360
New +$437K 0.06% 317

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Freedom Investment Management's ALXN Position: Q3 2021 in Review

Freedom Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5,718 shares — an estimated $1.05M sold.

Freedom Investment Management first reported a position in ALXN in Q4 2014 and held it in 27 quarters. The position peaked at $2.58M in Q2 2018. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Freedom Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Freedom Investment Management sold 5,718 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.05M.
  • Freedom Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 27 quarters.
  • Freedom Investment Management's Alexion Pharmaceuticals position peaked at $2.58M in Q2 2018.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Freedom Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.